Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Dietary Fiber, Microbiota and Cognitive Function in Healthy Adults (FOCUS)

1. Juli 2021 aktualisiert von: John Cryan, University College Cork

An Observational and Interventional Study on the Association Between Dietary Fibre and Cognitive Function in Healthy Volunteers

Dietary fiber is well-known for its many health benefits, including the support of gastrointestinal, metabolic, and mental health. Although studies investigating whole dietary patterns in relation to cognition have demonstrated that diet quality and a healthy dietary pattern are associated with better cognitive performance, the role of dietary fiber in this regard is understudied. In the last decade, the role of the microbiota (trillions of microbes inhabiting the gut) in influencing various aspects of human health, including mental health and behavior, has also become established. Importantly, dietary fiber has been shown to positively affect the microbiota composition.

In this study, the role of dietary fiber in cognition through the lens of the microbiota is investigated. A two-part study including an observational (study 1) and interventional (study 2) arm has been designed. In study 1, the observational arm, 150 healthy individuals (30-60 years of age) will be recruited and grouped into high-fiber (>25 g/day, n=75) and low-fiber (<18 grams/day, n=75) consumers based on habitual dietary intake. Cognitive tasks (attention, episodic memory, decision making), psychological dimensions including impulsivity and emotional reactivity, biological samples (feces, blood, saliva, urine) and questionnaires about general health will be collected. In study 2, the interventional arm, a subgroup (n=60) of individuals from the low-fiber group will further be randomized into an 8-week randomized-controlled, parallel, single-blinded intervention to either receive a high fiber (n=30, aim 30 grams/day) or control (n=30) diet education. During the intervention period, individuals will provide repeated fecal samples in order to assess temporal microbial changes. At the end of the intervention period, individuals will undergo the same testing regarding cognitive and psychological variables and the same biological samples will be collected.

The investigators hypothesize that participants with higher dietary fiber intake at baseline will perform better in the cognitive tasks compared to individuals with low fiber intake, and that this difference can, in part, be mediated by the gut microbiota. Further the investigators hypothesize that through the dietary intervention the microbiota composition will positively shift to include more beneficial microbes and that cognitive performance will improve following the intervention.

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Voraussichtlich)

150

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Gerard Clarke, PhD
  • Telefonnummer: 00353214901721
  • E-Mail: G.Clarke@ucc.ie

Studieren Sie die Kontaktsicherung

Studienorte

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

30 Jahre bis 60 Jahre (Erwachsene)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Be able to give written informed consent.
  • Be between 30 and 60 years of age.
  • Be in generally good health as determined by the investigator.

Exclusion Criteria:

  • Are less than 30 and greater than 60 years of age.
  • Have a significant acute or chronic coexisting illness [cardiovascular, gastrointestinal (GI) [to include functional GI disorders, inflammatory bowel disease, celiac disease, lactose intolerance, food allergies], immunological, psychiatric [to include formal or as determined by MINI Psychiatric interview, diagnosis of current major depression, anxiety disorder, bipolar spectrum disorder, schizophrenia, other DSM-IV Axis I disorder], neurodevelopmental disorders, immunological, metabolic disorders [to include type I or II diabetes], or any condition which contraindicates, in the investigators judgement, entry to the study,
  • Have a condition or taking a medication that the investigator believes would interfere with the objectives of the study, pose a safety risk or confound the interpretation of the study results; all psychoactive medications [to include anxiolytics, antipsychotics, antidepressants, anticonvulsants, centrally acting corticosteroids and opioid pain relievers), laxatives, enemas, antibiotics, anti-coagulants, over-the counter non-steroidal anti-inflammatories (NSAIDS). Participants should have a wash-out period of 4 weeks.
  • Current prebiotic or probiotic supplement use (a wash-out period of 4 weeks after cessation will allow entry to the study).
  • Females who are peri-menopausal, menopausal or post-menopausal.
  • Females who are pregnant or planning a pregnancy, or lactating.
  • Participants who are not fluent in English or English is not first language.
  • Are color blind.
  • Have dyslexia or dyscalculia.
  • Are a current habitual daily smoker.
  • Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the trial.
  • Participants receiving treatment involving experimental drugs. If the subject has been in a recent experimental trial, these must have been completed not less than 30 days prior to this study.
  • Have a malignant disease or any concomitant end-stage organ disease.
  • Have completed a study in the laboratory in the past 4 years.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Grundlegende Wissenschaft
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: DIET
Participants will receive four individual, approximately 30-minute long dietary education sessions. The participants will receive detailed instructions (including meal plans, information on high fiber foods and serving sizes) on how to consume at least 30 grams of fiber per day.
Sonstiges: High fiber diet
30 grams of fiber per day
Placebo-Komparator: CONTROL
No diet education. Group will spend same amount of time with study dietitian, but discussion is limited to review of current eating habits and minimal input on eating habits with referencing the standard food pyramid.
Sonstiges: Control diet
No diet education and change in diet

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Cognitive performance - Attention
Zeitfenster: Differences between groups at baseline and changes after 8-week of diet intervention in active group
Assessment of attention using the Paced Auditory Serial Addition Test (PASAT)
Differences between groups at baseline and changes after 8-week of diet intervention in active group
Cognitive performance - Episodic memory
Zeitfenster: Differences between groups at baseline and changes after 8-week of diet intervention in active group
Assessment of episodic memory using the Modified Rey Auditory Verbal Learning Test (ModRey)
Differences between groups at baseline and changes after 8-week of diet intervention in active group
Cognitive performance - Risky decision making
Zeitfenster: Differences between groups at baseline and changes after 8-week of diet intervention in active group
Assessment of risky decision making using the Cambridge Gambling Task (CGT)
Differences between groups at baseline and changes after 8-week of diet intervention in active group
Cognitive performance - Affective decision making
Zeitfenster: Differences between groups at baseline and changes after 8-week of diet intervention in active group
Assessment of affective decision making using the Iowa Gambling Task (IGT).
Differences between groups at baseline and changes after 8-week of diet intervention in active group

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Microbiota composition and function
Zeitfenster: Differences between groups at baseline and changes after 8-week of diet intervention in active group
Shotgun sequencing of fecal samples
Differences between groups at baseline and changes after 8-week of diet intervention in active group
Blood inflammatory profile
Zeitfenster: Differences between groups at baseline and changes after 8-week of diet intervention in active group
Cytokine and chemokine levels (e.g., TNFalpha, IL-10, IL-6) will be measured in lipopolysaccharide stimulated and unstimulated bloods
Differences between groups at baseline and changes after 8-week of diet intervention in active group
Salivary cortisol concentrations
Zeitfenster: Differences between groups at baseline and changes after 8-week of diet intervention in active group
Morning cortisol awakening response
Differences between groups at baseline and changes after 8-week of diet intervention in active group
Stress assessment
Zeitfenster: Differences between groups at baseline and changes after 8-week of diet intervention in active group
Perceived Stress Scale (range 0 to 40 with higher scores indicating higher perceived stress)
Differences between groups at baseline and changes after 8-week of diet intervention in active group
Anxiety assessment
Zeitfenster: Differences between groups at baseline and changes after 8-week of diet intervention in active group
State Trait Anxiety Inventory (range 20-80 with higher scores indicating higher anxiety)
Differences between groups at baseline and changes after 8-week of diet intervention in active group
Emotion sensitivity, intensity, and persistence
Zeitfenster: Differences between groups at baseline and changes after 8-week of diet intervention in active group
Emotion Reactivity Scale (range 0-84 with higher scores indicating higher dysfunctional emotional reactivity)
Differences between groups at baseline and changes after 8-week of diet intervention in active group
Impulsivity-related traits
Zeitfenster: Differences between groups at baseline and changes after 8-week of diet intervention in active group
UPPS-P Impulsive Behavior Scale (range 59-236 with higher scores indicating higher dysfunctional impulsivity
Differences between groups at baseline and changes after 8-week of diet intervention in active group

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

University College Cork

Ermittler

  • Hauptermittler: John F Cryan, PhD, APC Microbiome Ireland, University College Cork
  • Hauptermittler: Gerard Clarke, PhD, APC Microbiome Ireland, University College Cork

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Voraussichtlich)

1. Juli 2021

Primärer Abschluss (Voraussichtlich)

1. Juli 2023

Studienabschluss (Voraussichtlich)

1. Juli 2023

Studienanmeldedaten

Zuerst eingereicht

8. Juni 2021

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

1. Juli 2021

Zuerst gepostet (Tatsächlich)

7. Juli 2021

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

7. Juli 2021

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

1. Juli 2021

Zuletzt verifiziert

1. Juli 2021

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Andere Studien-ID-Nummern

  • APC135

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren